mutual
pharmaceutical
bartlett
argued
march
decided
june
federal
food
drug
cosmetic
act
fdca
requires
manufacturers
gain
food
drug
administration
fda
approval
marketing
generic
drug
interstate
commerce
drug
approved
manufacturer
prohibited
making
major
changes
qualitative
quantitative
formulation
drug
product
including
active
ingredients
specifications
provided
approved
application
cfr
generic
manufacturers
also
prohibited
making
unilateral
changes
drug
label
see
iii
respondent
prescribed
clinoril
version
nonsteroidal
drug
nsaid
sulindac
shoulder
pain
pharmacist
dispensed
generic
form
sulindac
manufactured
petitioner
mutual
pharmaceutical
respondent
soon
developed
acute
case
toxic
epidermal
necrolysis
severely
disfigured
physical
disabilities
nearly
blind
time
prescription
sulindac
label
specifically
refer
toxic
epidermal
necrolysis
however
fda
recommended
changing
nsaid
labeling
contain
explicit
toxic
epidermal
necrolysis
warning
respondent
sued
mutual
new
hampshire
state
mutual
removed
case
federal
jury
found
mutual
liable
respondent
claim
awarded
million
first
circuit
affirmed
relevant
found
neither
fdca
fda
regulations
respondent
claim
distinguished
pliva
mensing
held
claims
generic
manufacturers
fdca
prohibition
changes
generic
drug
labels
arguing
generic
manufacturers
facing
claims
comply
federal
state
law
simply
choosing
make
drug
held
claims
turn
adequacy
drug
warnings
federal
law
pliva
pp
supremacy
clause
state
laws
conflict
federal
law
without
effect
maryland
louisiana
even
absence
express
provision
state
law
may
impliedly
impossible
private
party
comply
state
federal
requirements
english
general
elec
impossible
mutual
comply
duty
alter
sulindac
label
composition
duty
either
strengthen
warnings
sulindac
label
change
sulindac
design
pp
new
hampshire
cause
action
imposes
affirmative
duties
manufacturers
including
duty
design
products
reasonably
safely
uses
foresee
thibault
sears
roebuck
pp
assess
whether
product
design
unreasonably
dangerous
user
vautour
body
masters
sports
industries
new
hampshire
employs
approach
asks
whether
danger
magnitude
outweighs
product
utility
repeatedly
identified
three
factors
germane
inquiry
usefulness
desirability
product
public
whole
whether
risk
danger
reduced
without
significantly
affecting
either
product
effectiveness
manufacturing
cost
presence
efficacy
warning
avoid
unreasonable
risk
harm
hidden
dangers
foreseeable
uses
ibid
increasing
drug
usefulness
reducing
risk
danger
require
redesigning
drug
since
factors
direct
results
drug
chemical
design
active
ingredients
however
redesign
possible
two
reasons
first
fdca
requires
generic
drug
active
ingredients
route
administration
dosage
form
strength
labeling
drug
equivalent
second
sulindac
simple
composition
drug
chemically
incapable
redesigned
accordingly
redesign
impossible
mutual
ameliorate
sulindac
profile
strengthening
warnings
thus
new
hampshire
law
ultimately
required
mutual
change
sulindac
labeling
pp
pliva
makes
clear
federal
law
prevents
generic
drug
manufacturers
changing
labels
see
accordingly
mutual
prohibited
taking
remedial
action
required
avoid
liability
new
hampshire
law
federal
law
forbids
action
required
state
law
state
law
without
effect
maryland
supra
impossible
mutual
comply
state
federal
law
new
hampshire
cause
action
respect
drugs
sold
interstate
commerce
pp
first
circuit
rationale
mutual
escape
impossibility
complying
duties
choosing
stop
selling
sulindac
incompatible
cases
presumed
actor
seeking
satisfy
obligations
required
cease
acting
altogether
pp
reversed
alito
delivered
opinion
roberts
scalia
kennedy
thomas
joined
breyer
filed
dissenting
opinion
kagan
joined
sotomayor
filed
dissenting
opinion
ginsburg
joined
opinion
notice
opinion
subject
formal
revision
publication
preliminary
print
reports
readers
requested
notify
reporter
decisions
washington
typographical
formal
errors
order
corrections
may
made
preliminary
print
goes
press
mutual
pharmaceutical
company
petitioner
karen
bartlett
writ
certiorari
appeals
first
circuit
june
justice
alito
delivered
opinion
must
decide
whether
federal
law
new
hampshire
claim
respondent
karen
bartlett
recovered
damages
petitioner
mutual
pharmaceutical
manufacturer
sulindac
generic
nonsteroidal
drug
nsaid
new
hampshire
law
imposes
duty
manufacturers
ensure
drugs
market
unreasonably
unsafe
drug
safety
evaluated
reference
chemical
properties
adequacy
warnings
mutual
unable
change
sulindac
composition
matter
federal
law
basic
chemistry
new
hampshire
cause
action
effectively
required
mutual
change
sulindac
labeling
provide
stronger
warnings
recognized
two
terms
ago
pliva
mensing
federal
law
prohibits
generic
drug
manufacturers
independently
changing
drugs
labels
accordingly
state
law
imposed
duty
mutual
comply
federal
law
supremacy
clause
state
laws
require
private
party
violate
federal
law
thus
without
effect
maryland
louisiana
appeals
solution
mutual
simply
pulled
sulindac
market
order
comply
state
federal
law
solution
rather
adopting
appeals
rationale
render
impossibility
dead
letter
work
revolution
case
law
accordingly
hold
claims
turn
adequacy
drug
warnings
federal
law
pliva
thus
reverse
decision
appeals
federal
food
drug
cosmetic
act
fdca
ch
stat
amended
et
drug
manufacturers
must
gain
approval
food
drug
administration
fda
marketing
drug
interstate
commerce
case
new
drug
fda
approval
secured
submitting
application
nda
nda
compilation
materials
must
include
full
reports
clinical
investigations
relevant
nonclinical
studies
data
information
relevant
evaluation
safety
effectiveness
drug
product
obtained
otherwise
received
applicant
source
cfr
iv
nda
must
also
include
labeling
proposed
used
drug
cfr
discussion
drug
benefits
exceed
risks
conditions
stated
labeling
cfr
viii
ix
fda
may
approve
nda
determines
drug
question
safe
use
conditions
use
prescribed
recommended
suggested
proposed
labeling
thereof
order
fda
consider
drug
safe
drug
probable
therapeutic
benefits
must
outweigh
risk
harm
fda
brown
williamson
tobacco
process
submitting
nda
onerous
lengthy
see
report
congressional
requesters
government
accountability
office
new
drug
development
biotechnology
typical
nda
spans
thousands
pages
based
clinical
trials
conducted
several
years
order
provide
swifter
route
approval
generic
drugs
congress
passed
drug
price
competition
patent
term
restoration
act
stat
popularly
known
act
generic
drug
may
approved
without
level
clinical
testing
required
approval
new
drug
provided
generic
drug
identical
drug
several
key
respects
first
proposed
generic
drug
must
chemically
equivalent
approved
drug
must
active
ingredient
active
ingredients
route
administration
dosage
form
strength
counterpart
ii
iii
second
proposed
generic
must
bioequivalent
approved
drug
iv
must
rate
extent
absorption
drug
third
generic
drug
manufacturer
must
show
labeling
proposed
new
drug
labeling
approved
approved
drug
drug
whether
generic
approved
manufacturer
prohibited
making
major
changes
qualitative
quantitative
formulation
drug
product
including
active
ingredients
specifications
provided
approved
application
cfr
generic
manufacturers
also
prohibited
making
unilateral
changes
drug
label
see
iii
approval
generic
drug
may
withdrawn
generic
drug
label
longer
consistent
drug
ii
fda
approved
nonsteroidal
pain
reliever
called
sulindac
brand
name
clinoril
clinoril
patent
expired
fda
approved
several
generic
sulindacs
including
one
manufactured
mutual
pharmaceutical
case
app
pet
cert
small
number
patients
nsaids
including
sulindac
popular
nsaids
ibuprofen
naproxen
serious
side
effect
causing
two
hypersensitivity
skin
reactions
characterized
necrosis
skin
mucous
membranes
toxic
epidermal
necrolysis
less
severe
cousin
syndrome
dorland
illustrated
medical
dictionary
ed
physicians
desk
reference
ed
friedman
orlet
still
law
toxic
epidermal
necrolysis
due
administration
celecobix
celebrex
southern
medical
december
respondent
karen
bartlett
prescribed
clinoril
shoulder
pain
pharmacist
dispensed
generic
form
sulindac
manufactured
petitioner
mutual
pharmaceutical
respondent
soon
developed
acute
case
toxic
epidermal
necrolysis
results
horrific
sixty
percent
surface
respondent
body
deteriorated
burned
turned
open
wound
spent
months
medically
induced
coma
underwent
eye
surgeries
year
severely
disfigured
number
physical
disabilities
nearly
blind
time
respondent
prescribed
sulindac
drug
label
specifically
refer
syndrome
toxic
epidermal
necrolysis
warn
drug
cause
severe
skin
reactions
atalities
app
supp
nh
internal
quotation
marks
omitted
however
syndrome
toxic
epidermal
necrolysis
listed
potential
adverse
reactions
drug
package
insert
respondent
already
suffering
toxic
epidermal
necrolysis
fda
completed
comprehensive
review
risks
benefits
including
risk
toxic
epidermal
necrolysis
approved
nsaid
products
decision
letter
fda
docket
june
online
http
visited
june
available
clerk
case
file
result
review
fda
recommended
changes
labeling
nsaids
including
sulindac
explicitly
warn
toxic
epidermal
necrolysis
app
respondent
sued
mutual
new
hampshire
state
mutual
removed
case
federal
respondent
initially
asserted
claims
district
dismissed
claim
based
doctor
admi
ssion
read
box
label
insert
trial
respondent
claim
jury
found
mutual
liable
awarded
respondent
million
damages
appeals
affirmed
relevant
found
neither
fdca
fda
regulations
respondent
claims
distinguished
pliva
mensing
held
claims
generic
manufacturers
fdca
prohibition
changes
generic
drug
labels
arguing
generic
manufacturers
facing
claims
simply
choose
make
drug
thus
comply
federal
state
law
granted
certiorari
iii
supremacy
clause
provides
laws
treaties
shall
law
land
thing
constitution
laws
state
contrary
notwithstanding
art
vi
cl
accordingly
long
settled
state
laws
conflict
federal
law
without
effect
maryland
louisiana
mcculloch
maryland
wheat
see
also
gade
national
solid
wastes
management
nder
supremacy
clause
doctrine
derived
state
law
however
clearly
within
state
acknowledged
power
interferes
contrary
federal
law
must
yield
internal
quotation
marks
omitted
even
absence
express
provision
found
state
law
impliedly
impossible
private
party
comply
state
federal
requirements
english
general
elec
see
also
florida
lime
avocado
growers
paul
holding
federal
exclusion
state
law
inescapable
requires
inquiry
congressional
design
compliance
federal
state
regulations
physical
impossibility
one
engaged
interstate
commerce
instant
case
impossible
mutual
comply
duty
strengthen
warnings
sulindac
label
duty
alter
sulindac
label
accordingly
state
law
begin
identifying
petitioner
duties
state
law
initial
matter
respondent
wrong
asserting
purpose
new
hampshire
designdefect
cause
action
compensatory
regulatory
brief
respondent
rather
new
hampshire
cause
action
imposes
affirmative
duties
manufacturers
respondent
correct
new
hampshire
adopted
doctrine
strict
liability
tort
set
forth
section
restatement
second
torts
see
restatement
second
torts
hereinafter
restatement
see
buttrick
arthur
lessard
sons
restatement
consequently
new
hampshire
tort
law
ne
sells
product
defective
condition
unreasonably
dangerous
user
consumer
property
subject
liability
physical
harm
thereby
caused
even
though
exercised
possible
care
preparation
sale
product
restatement
respondent
argument
conflates
call
regime
liability
depend
negligence
still
signals
breach
duty
call
regime
liability
reflect
breach
duties
merely
serves
spread
risk
new
hampshire
adopted
former
latter
indeed
new
hampshire
consistently
held
product
duty
design
product
reasonably
safely
uses
foresee
thibault
sears
roebuck
see
also
reid
spadone
mach
new
hampshire
manufacturer
general
duty
design
product
reasonably
safely
uses
foresee
internal
quotation
marks
omitted
chellman
ab
duty
warn
part
general
duty
design
manufacture
sell
products
reasonably
safe
foreseeable
uses
cf
simoneau
south
bend
lathe
limit
application
strict
tort
liability
jurisdiction
continuing
emphasize
liability
without
negligence
liability
without
fault
price
bic
cautioning
term
dangerous
interpreted
broadly
impose
absolute
liability
manufacturers
make
insurers
products
accordingly
respondent
incorrect
arguing
new
hampshire
system
imposes
substantive
duties
manufacturers
brief
respondent
new
hampshire
tort
law
imposes
duty
manufacturers
clear
determining
content
duty
requires
somewhat
analysis
discussed
greater
detail
new
hampshire
requires
manufacturers
ensure
products
design
manufacture
sell
unreasonably
dangerous
new
hampshire
recognized
duty
satisfied
either
changing
drug
design
changing
labeling
since
mutual
option
changing
sulindac
design
new
hampshire
law
ultimately
required
change
sulindac
labeling
respondent
argues
even
new
hampshire
law
impose
duty
drug
manufacturers
duty
encompass
either
duty
change
sulindac
design
duty
change
sulindac
labeling
brief
respondent
capitalization
emphasis
deleted
argument
correct
new
hampshire
imposes
liability
design
product
created
defective
condition
unreasonably
dangerous
user
vautour
body
masters
sports
industries
chellman
supra
determine
whether
product
unreasonably
dangerous
new
hampshire
employs
approach
product
defective
designed
magnitude
danger
outweighs
utility
product
vautour
supra
internal
quotation
marks
omitted
approach
requires
multifaceted
balancing
process
involving
evaluation
many
conflicting
factors
ibid
internal
quotation
marks
omitted
see
also
thibault
supra
set
factors
considered
ultimately
open
one
new
hampshire
repeatedly
identified
three
factors
germane
inquiry
usefulness
desirability
product
public
whole
whether
risk
danger
reduced
without
significantly
affecting
either
product
effectiveness
manufacturing
cost
presence
efficacy
warning
avoid
unreasonable
risk
harm
hidden
dangers
foreseeable
uses
vautour
supra
see
also
price
supra
chellman
supra
drug
context
either
increasing
usefulness
product
reducing
risk
danger
require
redesigning
drug
drug
usefulness
risk
danger
direct
results
chemical
design
saliently
active
ingredients
see
cfr
active
ingredient
means
component
intended
furnish
pharmacological
activity
direct
effect
diagnosis
cure
mitigation
treatment
prevention
disease
affect
structure
function
body
humans
italics
deleted
present
case
however
redesign
possible
two
reasons
first
fdca
requires
generic
drug
active
ingredients
route
dosage
form
strength
labeling
drug
based
ii
cfr
consequently
appeals
correct
recognize
mutual
legally
make
sulindac
another
composition
indeed
mutual
change
composition
sulindac
altered
chemical
new
drug
require
nda
marketed
interstate
commerce
see
cfr
giving
examples
fda
considers
drug
new
including
cases
involving
newness
drug
use
substance
composes
drug
whole
part
second
sulindac
simple
composition
drug
chemically
incapable
redesigned
see
mutual
legally
make
sulindac
another
composition
apparent
alter
drug
anyway
given
impossibility
redesigning
sulindac
way
mutual
ameliorate
drug
profile
thus
escape
liability
strengthen
presence
efficacy
sulindac
warning
way
warning
avoid
ed
unreasonable
risk
harm
hidden
dangers
foreseeable
uses
vautour
supra
see
also
chellman
duty
warn
part
general
duty
design
manufacture
sell
products
reasonably
safe
foreseeable
uses
design
product
makes
warning
necessary
avoid
unreasonable
risk
harm
foreseeable
use
lack
warning
ineffective
warning
causes
product
defective
unreasonably
dangerous
citation
omitted
thus
new
hampshire
cause
action
imposed
duty
mutual
strengthen
sulindac
warnings
reasons
unsurprising
allegations
sulindac
label
inadequate
featured
prominently
trial
respondent
introduced
evidence
label
mutual
sulindac
time
injuries
label
revised
respondent
suffered
injuries
app
counsel
opening
statement
informed
jury
evidence
show
sulindac
unreasonably
dangerous
inadequate
warning
well
hear
much
evidence
label
inadequate
relation
case
tr
district
repeatedly
instructed
jury
evaluate
sulindac
labeling
determining
whether
mutual
sulindac
unreasonably
dangerous
see
app
jury
instruction
jury
find
defect
design
found
sulindac
unreasonably
dangerous
warning
present
effective
avoid
unreasonable
danger
ibid
jury
instruction
design
defect
exists
warning
present
effective
avoid
unreasonable
danger
finally
district
clarified
order
opinion
denying
mutual
motion
judgment
matter
law
adequacy
sulindac
labeling
part
jury
instructed
consider
supp
jury
found
risks
outweighed
benefits
consider
whether
warning
regardless
adequacy
risks
extent
eliminated
unreasonable
danger
thus
accordance
new
hampshire
law
jury
presented
evidence
relevant
instructed
consider
whether
mutual
fulfilled
duty
label
sulindac
adequately
render
drug
unreasonably
dangerous
holding
mutual
liable
jury
determined
mutual
breached
duty
duty
imposed
federal
law
far
readily
apparent
pliva
made
clear
federal
law
prevents
generic
drug
manufacturers
changing
labels
see
slip
federal
drug
regulations
interpreted
fda
prevented
manufacturers
independently
changing
generic
drugs
safety
labels
see
also
labeling
proposed
new
drug
labeling
approved
approved
drug
cfr
iii
approval
generic
drug
may
withdrawn
generic
drug
label
longer
consistent
drug
thus
federal
law
prohibited
mutual
taking
remedial
action
required
avoid
liability
new
hampshire
law
federal
law
forbids
action
state
law
requires
state
law
without
effect
maryland
impossible
mutual
similarly
situated
manufacturers
comply
state
federal
new
hampshire
cause
action
respect
drugs
sold
interstate
iv
appeals
reasoned
mutual
escape
impossibility
complying
duties
choos
ing
make
sulindac
reject
rationale
incompatible
jurisprudence
cases
presume
actor
seeking
satisfy
obligations
required
cease
acting
altogether
order
avoid
liability
indeed
option
ceasing
act
defeated
claim
impossibility
impossibility
meaningless
slip
incoherence
theory
becomes
plain
viewed
lens
previous
cases
every
instance
found
impossibility
direct
conflict
duties
easily
avoided
regulated
actor
simply
ceased
acting
pliva
obvious
example
discussed
pliva
held
state
claims
fdca
impossible
drug
manufacturers
like
pliva
comply
duty
label
products
way
rendered
reasonably
safe
duty
change
drugs
labels
slip
course
possible
drug
manufacturers
like
pliva
pull
products
market
altogether
avoided
liability
state
federal
law
manufacturers
neither
labeled
products
way
rendered
unsafe
impermissibly
changed
federally
approved
label
concluding
impossible
manufacturers
comply
duty
change
label
federal
law
duty
keep
label
slip
undeterred
prospect
pliva
complied
state
federal
requirements
simply
leaving
market
appeals
decision
found
mensing
claims
escaped
based
rationale
first
circuit
relied
case
see
mensing
wyeth
eneric
defendants
compelled
market
metoclopramide
realized
label
insufficient
simply
stopped
selling
product
moreover
mensing
advanced
rationale
petition
rehearing
denied
pliva
supra
pet
nonetheless
squarely
determined
impossible
pliva
comply
state
federal
duties
slip
adopting
first
circuit
rationale
mean
pliva
also
vast
majority
cases
found
impossibility
wrongly
decided
prospect
regulated
actor
avoid
liability
state
federal
law
simply
leaving
market
undermine
impossibility
analysis
pliva
irrelevant
analysis
dreadful
injuries
products
liabilities
cases
arise
often
engender
passionate
responses
today
exception
justice
sotomayor
dissent
hereinafter
dissent
illustrates
sympathy
respondent
relieve
us
responsibility
following
law
dissent
accuses
us
incorrectly
assuming
federal
law
gives
pharmaceutical
companies
right
sell
federally
approved
drug
free
liability
post
make
assumption
rather
discussed
length
see
supra
hold
claims
like
new
hampshire
place
duty
manufacturers
render
drug
safer
either
altering
composition
altering
labeling
conflict
federal
laws
prohibit
manufacturers
unilaterally
altering
drug
composition
labeling
dissent
quite
correct
federal
law
establishes
drug
companies
prevent
taking
certain
remedial
measures
state
law
imposes
duty
take
remedial
measures
actual
ly
conflict
federal
law
making
private
party
comply
state
federal
requirements
freightliner
myrick
quoting
english
dissent
seems
acknowledge
point
concedes
federal
law
requires
particular
product
label
include
complete
list
ingredients
state
law
specifically
forbids
labeling
practice
little
question
state
law
yield
post
quoting
felder
casey
dissent
see
case
federal
law
requires
specific
label
sulindac
state
law
forbids
use
label
dissent
responds
new
hampshire
law
merely
create
incentive
alter
sulindac
label
composition
post
impose
actual
legal
obligation
post
contours
argument
difficult
discern
perhaps
dissent
drawing
distinction
exposure
liability
post
statutory
legal
mandate
ibid
distinction
common
law
statutory
law
irrelevant
argument
hand
violating
duty
surely
violating
statutory
duty
party
contravenes
law
true
certain
sense
duties
give
manufacturer
choice
exiting
market
continuing
sell
knowing
may
pay
compensation
consumers
injured
product
post
statutory
mandate
precisely
thing
require
manufacturer
choose
leaving
market
accepting
consequences
actions
form
fine
sanction
see
generally
calabresi
melamed
property
rules
liability
rules
inalienability
one
view
cathedral
harv
rev
discussing
liability
rules
event
pliva
dissent
agrees
involved
requirement
conflicted
federal
law
post
dealt
claims
see
pliva
supra
slip
pliva
controls
instant
case
dissent
reduced
fighting
rearguard
action
reasoning
despite
ostensibly
swearing
fealty
holding
suggest
bates
dow
agrosciences
llc
contrary
simply
misleading
dissent
correct
bates
held
texas
claim
claim
question
requirement
labeling
thus
fell
outside
class
claims
covered
express
provision
issue
case
emphasis
original
indeed
contrary
impression
one
might
draw
dissent
post
bates
actually
blessed
lower
determination
state
claim
imposed
requirement
appeals
however
correctly
hold
term
reaches
beyond
positive
enactments
statutes
regulations
embrace
duties
bates
supra
dissent
offers
compelling
reason
duty
case
similarly
viewed
requirement
agree
course
determining
precisely
specific
requirement
state
claim
imposes
important
post
bates
makes
clear
proper
inquiry
calls
examination
elements
duty
issue
call
speculation
whether
jury
verdict
prompt
take
particular
action
citation
omitted
tried
make
clear
duty
ensure
one
products
unreasonably
dangerous
imposed
new
hampshire
cause
action
vautour
involves
duty
make
one
several
changes
cases
impossible
fact
law
alter
product
design
thus
increase
product
usefulness
decrease
risk
danger
duty
render
product
reasonably
safe
boils
duty
ensure
presence
efficacy
warning
avoid
unreasonable
risk
harm
hidden
dangers
foreseeable
uses
duty
redesign
sulindac
label
thus
part
duty
issue
merely
action
mutual
might
prompted
take
adverse
jury
verdict
finally
dissent
laments
ignored
congress
explicit
efforts
preserve
state
liability
post
suffice
say
welcome
congress
explicit
resolution
difficult
questions
arise
prescription
drug
context
issue
repeatedly
vexed
produced
widely
divergent
views
recent
years
see
wyeth
levine
pliva
dissent
concedes
however
fdca
treatment
prescription
drugs
includes
neither
express
clause
vaccine
context
express
clause
drug
context
absence
sort
explicit
expression
congressional
intent
left
divine
congress
duties
statute
imposes
federal
law
forbids
mutual
take
actions
required
state
tort
law
evinces
intent
case
arises
tragic
circumstances
combination
factors
combined
produce
rare
devastating
injuries
respondent
suffered
fda
decision
approve
sale
sulindac
warnings
accompanied
drug
time
prescribed
decision
respondent
physician
prescribe
sulindac
despite
known
risks
congress
decision
regulate
manufacture
sale
generic
drugs
way
reduces
cost
patients
leaves
generic
drug
manufacturers
incapable
modifying
either
drugs
compositions
warnings
respondent
situation
tragic
evokes
deep
sympathy
straightforward
application
law
requires
judgment
reversed
ordered
breyer
dissenting
mutual
pharmaceutical
company
petitioner
karen
bartlett
writ
certiorari
appeals
first
circuit
june
justice
breyer
justice
kagan
joins
dissenting
literally
impossible
company
like
petitioner
comply
conflicting
state
federal
law
company
comply
either
business
relevant
state
paying
state
penalty
say
damages
failing
comply
tort
standard
see
post
sotomayor
dissenting
conflicting
state
law
requires
company
withdraw
state
pay
sizable
damages
remedy
order
avoid
conflict
state
federal
law
may
nonetheless
obstacle
accomplishment
federal
law
objective
case
relevant
state
law
post
quoting
crosby
national
foreign
trade
normally
reasons
set
forth
medtronic
lohr
opinion
concurring
part
concurring
judgment
deciding
whether
conflict
pay
particular
attention
views
relevant
agency
food
drug
administration
fda
statute
contains
clear
command
courts
may
infer
administrative
agency
degree
leeway
determine
extent
governing
statutes
rules
regulations
administrative
actions
effect
see
citing
smiley
citibank
south
dakota
hillsborough
county
automated
medical
laboratories
lawrence
county
school
dist
chevron
natural
resources
defense
council
see
also
wyeth
levine
cf
skidmore
swift
fda
responsible
administering
relevant
federal
statutes
question
may
call
considerable
expertise
indeed
one
might
infer
medically
valuable
drug
less
likely
congress
intended
permit
state
drive
marketplace
time
agency
develop
informed
position
question
providing
interested
parties
opportunity
present
views
translate
understandings
particular
intentions
accompanying
various
rules
regulations
communicate
intentions
statements
preambles
interpretive
statements
responses
comments
medtronic
supra
opinion
breyer
quoting
supra
however
give
special
weight
fda
views
one
thing
far
briefing
reveals
fda
developing
views
held
hearings
matter
solicited
opinions
arguments
views
public
ways
another
thing
fda
set
forth
positions
briefs
filed
litigation
regulations
interpretations
similar
agency
work
product
see
bowen
georgetown
univ
hospital
gency
litigating
positions
wholly
unsupported
regulations
rulings
administrative
practice
entitled
less
ordinary
weight
cf
christensen
harris
county
finally
fda
set
forth
conflicting
views
general
matter
different
briefs
filed
different
times
compare
wyeth
supra
noting
fda
previously
found
argued
new
position
entitled
deference
pliva
mensing
slip
declining
defer
argument
instead
finding
brief
amicus
curiae
arguing
see
national
cable
telecommunications
assn
brand
internet
services
agency
views
vary
time
accorded
less
weight
motor
vehicle
mfrs
assn
state
farm
mut
automobile
ins
verizon
communications
fcc
without
giving
agency
views
special
weight
conclude
impossible
petitioner
comply
state
federal
regulatory
schemes
federal
regulatory
scheme
state
common
law
read
potentially
requiring
petitioner
pay
damages
leave
market
two
former
fda
commissioners
tell
us
fda
long
believed
state
tort
litigation
supplemen
agency
regulatory
enforcement
activities
brief
donald
kennedy
et
al
amici
curiae
see
also
wyeth
supra
keeping
congress
decision
tort
suits
appears
fda
traditionally
regarded
state
law
complementary
form
drug
regulation
moreover
unlike
federal
statute
issue
medtronic
statute
us
contains
general
clause
see
cf
wyeth
supra
presence
clause
show
congress
thought
suits
posed
obstacle
objectives
furthermore
found
convincing
reason
believe
removing
particular
drug
new
hampshire
market
requiring
damage
payments
harmful
seriously
undercut
purposes
federal
statutory
scheme
cf
post
finally
similarly
situated
defendants
cases
remain
free
argue
obstacle
respect
damage
payments
market
withdrawal
demonstrate
type
conflict
particular
cases
might
create
true
incompatibility
state
federal
regulatory
schemes
reasons
respectfully
dissent
sotomayor
dissenting
mutual
pharmaceutical
company
petitioner
karen
bartlett
writ
certiorari
appeals
first
circuit
june
justice
sotomayor
justice
ginsburg
joins
dissenting
pliva
mensing
expanded
scope
impossibility
immunize
generic
drug
manufacturers
claims
today
unnecessarily
unwisely
extends
holding
mensing
new
hampshire
law
governing
respect
generic
drugs
takes
step
concluding
petitioner
mutual
pharmaceutical
held
liable
claim
disguise
even
though
district
clearly
rejected
claim
instead
allowed
liability
distinct
theory
see
infra
greater
consequence
appears
justify
revision
respondent
karen
bartlett
claim
undefended
assumption
federal
law
gives
pharmaceutical
companies
right
sell
federally
approved
drug
free
liability
remarkably
derives
proposition
federal
law
order
protect
consumers
prohibits
manufacturers
distributing
new
drugs
commerce
without
federal
regulatory
approval
specifically
disavows
intent
displace
state
law
absent
direct
positive
conflict
karen
bartlett
grievously
injured
drug
jury
found
unreasonably
dangerous
jury
relied
upon
evidence
drug
posed
higher
normal
risk
causing
serious
skin
reaction
produced
horrific
injuries
carried
risks
possessed
apparent
offsetting
benefits
compared
similar
pain
relievers
like
aspirin
see
supp
nh
laments
tragic
situation
ante
responsibility
fact
karen
bartlett
deprived
remedy
injuries
rests
established
principles
properly
applied
case
new
hampshire
law
correctly
construed
federal
law
pose
barrier
karen
bartlett
recovery
dissent
begin
two
cornerstones
jurisprudence
wyeth
levine
control
case
conspicuously
absent
majority
opinion
first
purpose
congress
ultimate
touchstone
every
case
ibid
quoting
medtronic
lohr
second
start
assumption
historic
police
powers
superseded
federal
act
unless
clear
manifest
purpose
congress
rice
santa
fe
elevator
assumption
explained
applies
particular
force
case
congress
legislated
field
traditionally
occupied
altria
group
good
applied
principles
food
drug
cosmetic
act
fdca
ch
stat
amended
et
levine
held
state
claim
drug
manufacturer
federal
law
tracing
history
federal
drug
regulation
federal
food
drugs
act
stat
fdca
major
amendments
explained
federal
drug
law
state
liability
long
understood
operate
tandem
promote
consumer
safety
see
levine
basic
principle
majority
opinion
elides
essential
understanding
case
fdca
prohibits
introduction
interstate
commerce
new
drug
without
prior
approval
food
drug
administration
fda
generic
drug
manufacturers
required
make
different
showings
receive
agency
approval
premarketing
review
process
see
ante
either
case
fda
permission
market
drug
never
regarded
final
stamp
approval
drug
safety
fdca
manufacturers
greater
access
information
drugs
fda
levine
retain
ultimate
responsibility
safety
products
sell
addition
ongoing
obligations
monitor
drug
risks
report
adverse
drug
responses
fda
see
cfr
manufacturers
may
sell
drug
deemed
misbranded
dangerous
health
used
dosage
manner
called
drug
label
see
brief
amicus
curiae
hereinafter
brief
indicating
misbranding
prohibition
may
apply
drug
previously
approved
sale
significant
new
scientific
evidence
demonstrates
drug
unsafe
beyond
federal
requirements
state
common
law
plays
important
complementary
role
federal
drug
regulation
levine
federal
law
area
initially
intended
supplemen
protection
consumers
already
provided
state
regulation
liability
congress
enlarged
fda
powers
took
care
preserve
state
law
amendments
fdca
established
fda
premarketing
review
modern
form
congress
adopted
saving
clause
providing
amendments
construed
invalidate
provision
state
law
absent
direct
positive
conflict
stat
years
since
state
suits
ing
unabated
fda
regulation
levine
quoting
riegel
medtronic
ginsburg
dissenting
congress
enacted
provision
prescription
drugs
whether
generic
even
enacted
provisions
respect
products
regulated
congress
preservation
role
state
law
generally
remedies
specifically
reflects
realistic
understanding
limitations
ex
ante
federal
review
context
even
rigorous
preapproval
clinical
testing
drugs
generally
incapable
detecting
adverse
effects
occur
infrequently
long
latency
periods
affect
subpopulations
included
adequately
represented
studies
kessler
vladeck
critical
examination
fda
efforts
preempt
claims
geo
see
national
academies
institute
medicine
future
drug
safety
promoting
protecting
health
public
hereinafter
future
drug
safety
discussing
limitations
inherent
system
premarket
clinical
trials
moreover
fda
tasked
monitoring
thousands
drugs
market
considering
new
drug
applications
faces
significant
resource
constraints
limit
ability
protect
public
dangerous
drugs
see
levine
brief
former
fda
commissioner
donald
kennedy
et
al
amici
curiae
tort
suits
help
fill
gaps
federal
regulation
serv
ing
catalyst
identify
previously
unknown
drug
dangers
bates
dow
agrosciences
llc
perhaps
significant
state
common
law
provides
injured
consumers
like
karen
bartlett
seek
redress
available
federal
law
nlike
administrative
legislative
regulations
claims
necessarily
perform
important
role
compensating
accident
victims
sprietsma
mercury
marine
always
consistent
issue
repeatedly
cautioned
reading
federal
statutes
remove
means
judicial
recourse
injured
congress
provide
federal
remedy
silkwood
see
bates
lohr
plurality
opinion
fact
legislative
history
fdca
suggests
congress
chose
create
federal
cause
action
damages
precisely
believed
state
tort
law
allow
injured
consumers
obtain
compensation
see
levine
ii
light
background
mutual
face
uphill
climb
show
federal
law
new
hampshire
claim
generic
drug
manufacturer
defective
design
majority
nevertheless
accepts
mutual
argument
compliance
federal
state
law
physical
impossibility
florida
lime
avocado
growers
paul
see
ante
state
law
properly
understood
clear
new
hampshire
claim
impose
legal
obligation
mutual
violate
federal
law
satisfy
impossibility
demanding
defense
requires
defendant
show
irreconcilable
conflict
federal
state
legal
obligations
silkwood
logic
underlying
true
impossibility
state
federal
law
impose
irreconcilable
affirmative
requirements
detailed
inquiry
congressional
necessary
inference
congress
intended
federal
law
displace
conflicting
state
requirement
inescapable
florida
lime
example
federal
law
requires
particular
product
label
include
complete
list
ingredients
state
law
specifically
forbids
labeling
practice
little
question
state
law
must
yield
felder
casey
key
inquiry
impossibility
identify
whether
state
federal
law
impose
directly
conflicting
affirmative
legal
obligations
state
law
require
act
unlawful
federal
law
california
fed
sav
loan
assn
guerra
impossibility
exist
laws
one
sovereign
permit
activity
laws
sovereign
restricts
even
prohibits
see
barnett
bank
marion
nelson
michigan
canners
freezers
agricultural
marketing
bargaining
modify
previous
example
federal
law
permitted
require
labeling
practice
state
law
prohibited
irreconcilable
conflict
manufacturer
comply
stringent
regulation
logic
impossibility
exist
one
sovereign
laws
merely
create
incentive
take
action
sovereign
authorized
possible
comply
laws
course
types
courts
may
find
state
laws
incentivize
federal
law
discourages
forbid
federal
law
authorizes
reasons
apart
impossibility
state
laws
may
fall
within
scope
express
provision
pose
obstacle
federal
purposes
objectives
intrude
upon
field
congress
intended
federal
law
occupy
exclusively
see
crosby
national
foreign
trade
council
absent
direct
conflict
two
mutually
incompatible
legal
requirements
impossibility
courts
may
automatically
assume
congress
intended
state
law
give
way
instead
careful
inquiry
congressional
intent
called
inquiry
informed
presumption
keeping
strict
standard
impossibility
cases
actually
find
basis
rare
see
abrams
plenary
power
preemption
rev
mensing
outlier
found
impossibility
generic
drug
manufacturer
strengthen
product
label
come
line
duty
warn
without
exercise
judgment
fda
see
slip
nothing
mensing
precedent
dictates
finding
impossibility
assess
whether
physically
impossible
mutual
comply
federal
state
law
necessary
identify
precision
relevant
legal
obligations
imposed
new
hampshire
cause
action
majority
insists
mutual
required
new
hampshire
law
strengthen
warning
label
taking
position
majority
effectively
bartlett
claim
de
facto
claim
majority
relies
hold
jury
found
mutual
liable
failing
fulfill
duty
label
sulindac
adequately
mensing
forbids
generic
drug
manufacturer
independently
alter
safety
label
ante
see
mensing
slip
majority
assertion
mutual
held
liable
case
violating
legal
obligation
change
label
inconsistent
new
hampshire
state
law
record
part
mutual
addition
making
argument
embraced
majority
contends
new
hampshire
law
effectively
required
change
chemical
composition
sulindac
mutual
claims
physically
impossible
comply
duty
consistent
federal
law
drug
manufacturers
may
change
chemical
composition
products
create
new
drugs
without
submitting
new
drug
application
fda
approval
see
cfr
new
hampshire
law
impose
legal
obligation
mutual
change
label
also
mandate
mutual
change
drug
design
following
blackletter
products
liability
law
restatement
second
torts
hereinafter
second
restatement
new
hampshire
recognizes
strict
liability
three
different
types
product
defects
manufacturing
defects
design
defects
warning
defects
see
cheshire
medical
center
grace
district
granted
mutual
summary
judgment
bartlett
claim
new
hampshire
cause
action
remains
issue
case
product
defective
design
new
hampshire
law
poses
unreasonable
dangers
consumers
thibault
sears
roebuck
determine
whether
product
unreasonably
dangerous
jury
asked
make
assessment
considering
nonexhaustive
list
factors
see
ante
addition
new
specifically
rejected
doctrine
advocated
restatement
third
torts
products
liability
hereinafter
third
restatement
plaintiff
must
present
evidence
reasonable
alternative
design
show
product
design
defective
instead
proof
alternative
design
relevant
design
defect
case
neither
controlling
factor
essential
element
vautour
body
masters
sports
industries
jurisdictions
declined
apply
liability
prescription
drugs
new
hampshire
common
many
jurisdictions
subject
prescriptions
drugs
distinct
form
strict
products
liability
see
citing
brochu
ortho
pharmaceutical
see
also
third
restatement
comment
collecting
cases
jurisdictions
drug
manufacturers
new
hampshire
affirmative
defense
comment
second
restatement
exempts
navoidably
unsafe
products
strict
liability
product
properly
manufactured
labeled
explained
lower
courts
case
see
supp
nh
new
hampshire
takes
approach
comment
defendant
seeking
invoke
defense
must
first
show
product
highly
useful
imposed
product
avoided
feasible
alternative
design
see
brochu
comment
factor
jury
assessment
liability
case
mutual
abandoned
comment
defense
trial
ante
claim
applied
mutual
subjects
manufacturer
unreasonably
dangerous
product
liability
require
manufacturer
take
specific
action
forbidden
federal
law
specifically
contrary
majority
see
ante
new
hampshire
law
require
mutual
change
warning
label
drug
warning
label
one
factor
nonexclusive
list
evaluating
whether
drug
unreasonably
dangerous
see
vautour
adequate
label
therefore
neither
necessary
sufficient
avoiding
liability
likewise
new
hampshire
law
imposed
duty
mutual
change
sulindac
chemical
composition
new
hampshire
held
proof
alternative
design
element
claim
see
kelleher
marvin
lumber
cedar
majority
recognizes
ante
sulindac
realistically
capable
redesigned
anyway
sure
new
hampshire
claim
creates
incentive
drug
manufacturers
make
changes
product
including
drug
label
try
avoid
liability
respondent
overstates
case
somewhat
suggests
new
hampshire
law
purely
compensatory
see
brief
respondent
typically
true
regimes
new
hampshire
law
mandates
compensation
defective
products
serves
compensatory
regulatory
purposes
see
heath
sears
roebuck
exposure
liability
incidental
regulatory
effects
flow
exposure
goodyear
atomic
miller
equivalent
legal
mandate
regulated
party
take
refrain
taking
specific
action
difference
significant
one
mandate
leaves
choice
party
wishes
comply
law
whereas
incentive
may
influence
choice
cases
reflect
distinction
bates
rejected
argument
claims
brought
pesticide
manufacturer
likely
induce
manufacturer
change
product
label
thus
run
afoul
express
provision
forbidding
state
labeling
requirements
different
addition
federal
requirements
requirement
explained
rule
law
must
obeyed
event
jury
verdict
merely
motivates
optional
decision
rise
level
fact
imposing
strict
liability
injuries
caused
defective
drug
design
might
make
drug
manufacturer
want
change
label
design
mean
manufacturer
actually
required
state
law
take
either
action
absent
legal
obligation
majority
impossibility
argument
get
ground
state
requirement
physically
impossible
mutual
comply
also
following
federal
law
case
therefore
unlike
mensing
undisputed
applicable
state
tort
law
require
drug
manufacturer
aware
product
danger
strengthen
label
requirement
conflicted
federal
law
preventing
manufacturer
slip
new
hampshire
law
require
anything
compensate
consumers
injured
unreasonably
dangerous
drug
moreover
trial
record
case
confirms
majority
insistence
mutual
held
liable
breach
ing
duty
label
sulindac
adequately
ante
bartlett
filed
suit
mutual
raised
distinct
claims
based
design
defect
failure
warn
app
see
supp
nh
pursuing
claims
consistent
new
hampshire
law
recognition
design
defect
failure
warn
claims
separate
leblanc
american
honda
motor
district
granted
summary
judgment
mutual
claim
repeatedly
explained
alleged
failure
warn
mutual
provide
basis
bartlett
recovery
see
supp
majority
notes
district
admitted
evidence
regarding
sulindac
label
ante
label
remained
relevant
limited
purpose
assessing
combination
factors
whether
sulindac
design
defective
product
unreasonably
dangerous
see
district
instructions
jury
adhered
limited
purpose
first
told
jury
determine
whether
sulindac
unreasonably
dangerous
weighing
danger
utility
app
instructed
jury
determined
sulindac
unreasonably
dangerous
without
reference
warning
label
consider
presence
efficacy
label
evaluate
whether
product
unreasonably
dangerous
even
warning
words
hold
mutual
liable
jury
required
find
sulindac
unreasonably
dangerous
despite
warning
district
also
explained
jury
bartlett
claim
addressed
whether
sulindac
design
defective
mutual
conduct
included
failure
change
warning
relevant
case
supp
distinction
drawn
district
permissible
impermissible
uses
evidence
regarding
sulindac
label
faithful
new
hampshire
law
law
recognizes
effectiveness
warning
label
one
relevant
factor
determining
whether
product
design
unreasonably
dangerous
claims
separate
leblanc
short
district
made
clear
mutual
held
liable
failing
change
warning
given
distinction
new
hampshire
draws
claims
claims
well
clear
repeated
statements
trial
judge
mutual
liability
predicated
breaching
duty
label
sulindac
adequately
basis
majority
reach
contrary
conclusion
though
majority
insists
otherwise
ante
appears
rely
principally
implicit
assumption
rights
conferred
federal
premarket
approval
fdca
correctly
observing
changing
sulindac
chemical
composition
create
new
drug
go
approval
process
majority
reasons
mutual
must
duty
change
label
option
avoid
liability
continuing
sell
product
ante
conclusion
based
false
premise
manufacturer
drug
unreasonably
dangerous
new
hampshire
law
multiple
options
change
drug
design
label
effort
alter
profile
remove
drug
market
pay
compensation
cost
business
federal
law
drug
chemical
properties
take
redesign
option
table
mean
manufacturer
suddenly
legal
obligation
state
law
improve
drug
label
indeed
view
state
law
makes
little
sense
even
mutual
strengthened
label
fully
account
sulindac
risks
company
might
still
faced
liability
defective
design
see
thibault
explaining
strict
liability
may
attach
even
though
adequate
warning
manufacturer
change
label
make
drug
safe
manufacturer
may
still
choose
exiting
market
continuing
sell
knowing
may
pay
compensation
consumers
injured
manufacturer
perspective
may
choice
choice
sovereign
state
may
impose
protect
citizens
dangerous
drugs
least
ensure
seriously
injured
consumers
receive
compensation
state
may
impose
choice
unless
fdca
gives
manufacturers
absolute
right
sell
products
free
liability
state
law
otherwise
stands
obstacle
accomplishment
federal
objectives
crosby
internal
quotation
marks
omitted
majority
rely
obstacle
must
believe
manufacturer
received
fda
premarket
approval
right
keep
drug
market
unless
fda
revokes
approval
also
free
liability
makes
expensive
proposition
fundamentally
inconsistent
fdca
text
structure
saving
clause
see
supra
levine
thomas
concurring
judgment
simply
incorrect
say
federal
law
presupposes
drug
manufacturers
right
continue
sell
drug
free
liability
approved
nothing
language
fdca
framed
prohibition
distribution
without
fda
approval
see
suggests
right
federal
law
bars
sale
previously
approved
drugs
new
information
comes
light
demonstrating
drug
dangerous
health
thus
misbranded
see
see
supra
even
outside
scenario
manufacturers
regularly
take
drugs
market
evidence
emerges
drug
risks
particularly
safer
drugs
provide
therapeutic
benefits
according
fda
formal
authority
withdraw
approval
drug
based
new
adverse
information
see
far
common
manufacturer
stop
selling
product
voluntarily
fda
advises
manufacturer
drug
unsafe
profile
adequately
addressed
labeling
changes
measures
see
brief
new
hampshire
cause
action
thus
provide
impetus
action
permitted
sometimes
encouraged
even
required
federal
law
majority
derides
suggestion
mutual
ability
stop
selling
sulindac
relevant
validity
impossibility
defense
ante
majority
argument
built
mistaken
premise
mutual
legally
obligated
new
hampshire
law
modify
label
way
federal
law
forbids
see
supra
reason
rejecting
impossibility
render
doctrine
dead
letter
meaningless
ante
quoting
mensing
slip
hand
majority
work
revolution
impossibility
case
law
ante
inferring
requirement
steps
manufacturer
might
wish
take
avoid
mitigate
exposure
liability
products
made
safe
sale
improved
warning
tweak
design
new
hampshire
law
made
judgment
drugs
initially
approved
distribution
turn
inherently
unreasonably
dangerous
therefore
sold
unless
manufacturer
willing
compensate
injured
consumers
congressional
intent
cause
action
gleaned
existence
federal
specifications
apply
product
sold
instead
whether
new
hampshire
depends
assessing
whether
poses
obstacle
federal
policy
approve
sulindac
use
yet
skips
analysis
instead
finds
impossibility
exist
relying
assumption
congress
intended
mutual
way
continue
selling
sulindac
without
incurring
liability
see
ante
distinction
impossibility
obstacle
important
one
obstacle
abused
courts
apply
overly
broad
conception
relevant
federal
purpose
find
see
levine
thomas
concurring
judgment
useful
framework
case
like
one
least
lead
ask
right
questions
example
properly
evaluating
asserted
conflict
lens
obstacle
allow
consider
evidence
whether
congress
intended
fda
make
optimal
safety
determination
set
maximum
safety
standard
case
state
tort
law
undermine
purpose
rather
minimal
safety
threshold
case
state
tort
law
supplement
see
williamson
mazda
motor
america
slip
contrast
majority
overbroad
impossibility
framework
takes
account
federal
drug
safety
review
actually
works
though
majority
gestures
rigorous
nature
fda
review
new
drug
ante
nothing
majority
reasoning
turns
fda
premarketing
review
operates
agency
capacity
engage
postmarketing
review
taking
approach
majority
replaces
careful
assessment
regulatory
structure
ipse
dixit
pharmaceutical
companies
must
way
escape
liability
ante
continuing
sell
drug
received
fda
approval
result
effectively
makes
highly
contested
policy
judgment
relationship
fda
review
state
tort
law
treating
fda
sole
guardian
drug
safety
without
defending
judgment
without
whether
policy
judgment
congress
iii
majority
never
addresses
obstacle
mutual
argue
alternative
bartlett
cause
action
conflicts
purposes
objectives
fdca
supplemented
act
stat
though
presents
closer
question
impossibility
argument
majority
relies
reject
mutual
obstacle
defense
well
mutual
substantial
contention
new
claim
frustrates
policy
fdca
broader
scheme
vesting
authority
fda
expert
agency
determine
drug
designs
enter
remain
interstate
commerce
fda
amicus
brief
filed
generally
supports
argument
fda
question
whether
difficult
close
recognizes
everal
factors
weigh
favor
finding
preemption
including
absence
textual
support
fdca
idea
approved
drug
must
made
available
particular
state
see
brief
fda
ultimately
contends
claims
unless
parallel
fdca
misbranding
prohibition
agency
permitting
juries
balance
health
risks
benefits
drug
undermine
fda
determinations
reduce
access
drugs
fda
determined
safe
effective
cases
given
weight
agency
views
impact
tort
law
federal
objectives
subject
matter
technica
relevant
history
background
complex
extensive
levine
quoting
geier
american
honda
motor
courts
defe
agency
conclusion
state
law
tension
fda
identifies
effort
justify
complete
claims
prescription
drugs
satisfy
high
threshold
must
met
state
law
conflicting
purposes
federal
act
chamber
commerce
america
whiting
slip
internal
quotation
marks
omitted
see
silkwood
given
fdca
core
purpose
protecting
consumers
recognition
levine
state
tort
law
generally
complements
statute
safety
goals
practical
limits
fda
ability
monitor
promptly
address
concerns
drug
safety
drug
market
see
supra
absence
federal
remedy
injured
consumers
reject
broad
obstacle
argument
iv
troubling
aspect
majority
decision
expand
scope
traditionally
narrow
impossibility
doctrine
implies
relationship
federal
premarket
review
state
remedies
generally
central
majority
holding
assumption
manufacturers
must
way
avoid
keeping
particular
products
commerce
see
ante
assumption
seems
always
create
automatic
conflict
federal
premarket
review
requirement
liability
premarket
review
definition
prevents
manufacturers
unilaterally
changing
products
true
example
designs
chemical
composition
drugs
fdca
less
generic
drugs
see
ante
creation
automatic
conflict
ultimate
majority
continued
expansion
impossibility
result
frankly
astonishing
congress
adopted
fdca
premarketing
approval
requirement
strengthened
response
serious
episodes
involving
unsafe
drugs
see
future
drug
safety
yet
majority
lights
act
creating
requirement
order
safeguard
consumer
sullivan
also
created
operation
law
shield
drug
manufacturers
avoid
paying
damages
state
laws
also
designed
protect
consumers
notwithstanding
congress
effort
disclaim
intent
state
law
see
supra
majority
reasoning
thus
effect
granting
broad
immunity
entire
industry
judgment
congress
needed
stringent
regulation
riegel
ginsburg
dissenting
quoting
lohr
plurality
opinion
expanded
notion
impossibility
threatens
disturb
considerable
amount
state
law
fdca
premarket
approval
process
prescription
drugs
provided
model
regulation
many
statutes
congress
paired
premarket
regulatory
review
express
provisions
limit
application
state
remedies
including
instances
claims
defective
product
design
see
riegel
see
supra
instances
prescription
drugs
majority
approach
appears
claims
categorically
displaced
either
way
congress
efforts
set
boundaries
precisely
largely
academic
serious
consequences
product
safety
state
laws
play
important
role
discovering
risks
also
providing
manufacturers
remove
dangerous
products
market
promptly
see
levine
bates
see
also
conk
design
defect
restatement
third
torts
products
liability
yale
tort
system
encourage
fda
regulatory
vigor
competence
manufacturers
products
require
preapproval
given
de
facto
immunity
liability
public
rely
exclusively
imperfect
federal
agencies
limited
resources
sometimes
limited
legal
authority
recall
approved
products
consumers
injured
products
recourse
manner
congress
addressed
respect
vaccines
particularly
instructive
accines
subject
federal
premarket
approval
process
prescription
drugs
prior
congress
intervention
compensation
injuries
ha
left
largely
bruesewitz
wyeth
llc
slip
response
rise
tort
suits
produced
instability
vaccine
market
congress
enacted
national
childhood
vaccine
injury
act
vaccine
act
act
established
compensation
program
funded
excise
tax
vaccines
compensate
individuals
injured
killed
vaccine
side
effects
quid
pro
quo
system
stated
bruesewitz
provision
significant
protections
vaccine
manufacturers
slip
members
disagreed
scope
tort
protections
vaccine
act
intended
offer
act
history
demonstrates
congress
perfectly
capable
responding
believes
state
tort
law
may
compromise
significant
federal
objectives
scheme
premarket
regulatory
review
products
wants
make
available
illustrates
important
reason
require
preemption
decisions
made
congress
rather
courts
basis
expanded
implied
doctrine
congress
ability
tie
decisions
alternative
means
securing
compensation
metzger
federalism
agency
reform
colum
rev
instead
reaching
find
context
congress
never
intended
majority
leaves
consumers
like
karen
bartlett
bear
enormous
losses
recognizes
case
arises
tragic
circumstances
ante
doubt
members
majority
personally
feel
sympathy
karen
bartlett
solemn
affirmation
merely
discharges
duty
follo
law
ante
gives
effect
congress
policy
judgment
rather
hard
accept
expanding
scope
impossibility
turns
congress
intent
head
arrives
holding
irreconcilable
precedents
result
left
seriously
injured
consumer
without
remedy
despite
congress
explicit
efforts
preserve
state
liability
respectfully
dissent
footnotes
thus
save
another
day
question
whether
true
system
give
rise
impossibility
noted
causes
action
negligence
strict
liability
exist
merely
spread
risk
rather
impose
affirmative
duties
see
riegel
medtronic
medtronic
lohr
five
justices
concluded
causes
action
negligence
strict
liability
impose
federal
requirements
specific
medical
device
adhere
view
absent
indication
reference
state
includes
duties
plurality
opinion
said
cipollone
liggett
group
liability
existence
legal
duty
tort
judgment
therefore
establishes
defendant
violated
obligation
mutual
liability
turned
adequacy
sulindac
warnings
unusual
rather
new
hampshire
like
large
majority
adopted
comment
restatement
second
torts
recognizes
especially
common
field
drugs
products
incapable
made
safe
intended
ordinary
use
restatement
bellotte
zayre
comment
uch
product
properly
prepared
accompanied
proper
directions
warning
defective
unreasonably
dangerous
restatement
previously
noted
large
number
courts
took
comment
mean
manufacturers
face
strict
liability
side
effects
properly
manufactured
prescription
drugs
accompanied
adequate
warnings
bruesewitz
wyeth
slip
mutual
withdrew
comment
defense
purposes
trial
matter
defendant
notice
withdrawal
defenses
case
nh
however
noted
respondent
trial
injected
broader
question
adequacy
sulindac
label
trial
proceedings
justice
breyer
argues
literally
impossible
mutual
comply
state
federal
law
escape
liability
either
business
relevant
state
paying
state
penalty
say
damages
failing
comply
tort
standard
post
dissenting
opinion
infra
leaving
aside
rare
case
state
federal
law
actually
requires
product
pulled
market
cases
presume
manufacturer
ability
stop
selling
turn
impossibility
possibility
see
florida
lime
avocado
growers
paul
impossibility
dual
compliance
federal
orders
forbade
picking
marketing
avocado
testing
oil
california
test
excluded
state
avocado
measuring
less
oil
content
course
pliva
mensing
forecloses
argument
impossibility
defeated
prospect
manufacturer
pa
state
penalty
violating
duty
prospect
defeated
impossibility
pliva
well
see
slip
impossible
manufacturers
comply
duty
change
label
federal
law
duty
keep
label
hold
otherwise
render
impossibility
meaningless
slip
address
state
claims
parallel
federal
misbranding
statute
misbranding
statute
requires
pull
even
drug
market
dangerous
health
even
used
dosage
manner
frequency
duration
prescribed
recommended
suggested
labeling
thereof
cf
bates
dow
agrosciences
llc
pesticide
labeling
requirement
express
provision
provided
equivalent
fully
consistent
federal
misbranding
provisions
parties
government
appear
agree
drug
misbranded
federal
law
liability
based
new
scientifically
significant
information
fda
jury
asked
find
whether
new
evidence
concerning
sulindac
made
available
fda
rendered
sulindac
dangerous
misbranded
federal
misbranding
statute
misbranding
provision
applicable
cf
supp
nh
respondent
experts
testimony
drawn
directly
medical
literature
published
fda
analyses
respondent
attempts
distinguish
case
pliva
arguing
pliva
state
law
imposes
affirmative
duty
manufacturer
improve
product
label
suspending
sales
comply
duty
merely
offers
indirect
means
avoiding
liability
noncompliance
duty
brief
respondent
difference
purely
semantic
duty
pliva
amend
metoclopramide
label
easily
phrased
duty
sell
drug
without
adequate
warnings
least
state
imposes
liability
based
balancing
product
harms
benefits
light
labeling
rather
directly
prohibiting
product
sale
mere
fact
manufacturer
may
avoid
liability
leaving
market
defeat
claim
impossibility
footnotes
majority
failure
adhere
presumption
well
illustrated
fact
majority
calls
congress
provide
greater
clarity
regard
difficult
questions
arise
prescription
drug
context
ante
certainly
clear
direction
congress
questions
useful
whole
point
presumption
congressional
ambiguity
cut
favor
preserving
state
autonomy
see
rice
santa
fe
elevator
see
medical
devices
labeling
requirements
nonprescription
drugs
labeling
packaging
requirements
cosmetics
vaccines
instructively
congress
included
saving
clause
statutes
addressing
nonprescription
drugs
cosmetics
makes
clear
express
provisions
statutes
affect
state
product
liability
law
see
though
majority
rely
comment
find
misleadingly
implies
new
hampshire
like
large
majority
applied
comment
categorically
prescription
drugs
exempt
manufacturers
liability
side
effects
properly
manufactured
prescription
drugs
accompanied
warnings
ante
quoting
bruesewitz
wyeth
llc
slip
incorrect
majority
also
neglects
mention
courts
applied
comment
categorically
prescription
drug
designs
ost
courts
stated
justification
giving
prescription
drug
manufacturers
blanket
immunity
strict
liability
comment
american
law
products
liability
like
new
hampshire
courts
courts
apply
comment
basis
see
frumer
friedman
products
liability
pp
feature
new
hampshire
law
unnecessary
consider
whether
analysis
differ
jurisdiction
required
proof
feasible
alternative
design
element
liability
majority
suggests
account
bates
simply
misleading
ante
simply
misses
point
recognize
precedents
duties
may
qualify
requirements
least
term
used
express
provisions
federal
law
see
riegel
medtronic
determining
precisely
specific
requirement
state
claim
imposes
important
bates
lower
accepted
basic
argument
majority
advances
plaintiffs
claim
pesticide
unreasonably
dangerous
merely
disguised
claim
failure
warn
success
claim
pesticide
dangerous
crops
soil
certain
ph
level
necessarily
induce
manufacturer
change
product
label
avoid
liability
dow
agrosciences
llc
bates
explicitly
rejected
notion
liability
might
lead
manufacturer
make
label
change
meant
state
claim
imposed
requirement
labeling
packaging
see
majority
contends
case
different
duty
redesign
sulindac
label
element
new
hampshire
law
ante
see
supra
rather
altering
product
label
merely
one
step
manufacturer
might
take
prevent
product
considered
unreasonably
dangerous
step
new
hampshire
law
recognizes
may
insufficient
see
infra
example
ruling
proposed
jury
instructions
district
made
clear
bartlett
allowed
circumvent
summary
judgment
ruling
using
sulindac
warning
establish
drug
unreasonably
dangerous
arguing
sulindac
unreasonably
dangerous
warning
already
ruled
inadequacy
warning
cause
bartlett
injuries
app
explained
effectively
turn
case
back
case
rendering
summary
judgment
ruling
meaningless
ibid
district
later
told
counsel
removed
instruction
jury
instructions
failure
warn
case
admonished
counsel
tread
arguing
warning
label
label
adequacy
issue
jury
extent
majority
believes
district
practice
allowed
adequacy
warning
label
play
greater
role
trial
see
ante
irrelevant
question
statements
counsel
even
improper
change
state
law
cause
action
evaluate
purposes
appeals
specifically
concluded
district
jury
instructions
appropriate
mutual
wanted
caution
instructions
concerning
warning
label
mutual
sought
majority
suggestion
manufacturer
option
continuing
sell
paying
compensation
akin
violating
statutory
mandate
suffering
consequence
paying
fine
flawed
see
ante
scenario
manufacturer
violated
law
fact
law
enforced
monetary
sanctions
rather
injunction
imprisonment
change
matter
many
times
majority
insists
otherwise
manufacturer
sells
drug
whose
design
found
unreasonably
dangerous
based
balance
factors
violated
state
law
requiring
change
label
cases
manufacturer
may
owe
money
former
failed
follow
law
cf
national
federation
independent
business
sebelius
slip
recognizing
condition
triggers
tax
necessarily
legal
command
take
certain
action
majority
properly
leaves
open
question
whether
state
claims
parallel
federal
misbranding
statute
see
ante
majority
fails
appreciate
however
statute
undermines
impossibility
argument
compared
argument
based
obstacle
shows
federal
right
obligation
continue
sell
drug
like
sulindac
previously
approved
fact
statute
demonstrates
sometimes
drug
manufacturer
like
mutual
may
federal
duty
sell
drug
see
government
accountability
office
drug
safety
improvement
needed
fda
postmarket
oversight
process
noting
drugs
voluntarily
withdrawn
safety
reasons
wysowski
swartz
adverse
drug
event
surveillance
drug
withdrawals
archives
internal
med
noting
drugs
drug
products
withdrawn
market
safety
reasons
defending
policy
judgment
treats
fda
exclusive
guarantor
drug
safety
easy
task
light
evidence
resource
constraints
gaps
legal
authority
among
factors
limit
agency
ability
safeguard
public
health
see
kessler
vladeck
critical
examination
fda
efforts
preempt
claims
geo
see
also
wyeth
levine
fda
purports
address
calls
pure
claim
references
third
restatement
way
illustration
fda
separate
discussion
pure
claim
based
premise
new
hampshire
claim
turns
adequacy
drug
warning
see
brief
incorrect
see
supra
note
confronted
case
fda
promulgated
lawful
specific
regulations
describing
whether
circumstances
state
liability
interferes
safe
medical
care
sought
fdca
levine
breyer
concurring
see
also
ante
breyer
dissenting
least
creates
automatic
conflict
caveat
claims
parallel
federal
duty
manufacturers
withdraw
product
might
see
ante
see
pesticides
food
additives
animal
drugs
certain
medical
devices
color
additives
